<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29669" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Sulfasalazine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Choi</surname>
            <given-names>Jaehwa</given-names>
          </name>
          <aff>Mercer University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fenando</surname>
            <given-names>Ardy</given-names>
          </name>
          <aff>Michigan State University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jaehwa Choi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ardy Fenando declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29669.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Sulfasalazine, a potent disease-modifying antirheumatic drug (DMARD), helps manage&#x000a0;autoimmune conditions like rheumatoid arthritis and inflammatory bowel disease. This activity&#x000a0;discusses sulfasalazine's therapeutic indications, contraindications, and mechanism of action, crucial elements indispensable for the interdisciplinary team involved in patient care. Moreover, the activity&#x000a0;focuses&#x000a0;on adverse events and other essential facets of sulfasalazine therapy, ensuring healthcare professionals can navigate its complexities to optimize patient outcomes. By exploring off-label applications, pharmacokinetics, monitoring protocols, and clinical toxicology, participants gain an excellent grasp of sulfasalazine's utility, enabling them to tailor treatment strategies for individuals with inflammatory bowel disease, rheumatoid arthritis, and polyarticular juvenile idiopathic arthritis. With this understanding, healthcare practitioners can fine-tune therapeutic regimens to meet diverse patient needs, enhancing sulfasalazine therapy's efficacy and precision across various clinical contexts.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe&#x000a0;the mechanism of action of sulfasalazine.</p></list-item><list-item><p>Identify&#x000a0;the adverse effects and contraindications of sulfasalazine.</p></list-item><list-item><p>Determine&#x000a0;appropriate monitoring steps and toxicity of sulfasalazine.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from sulfasalazine therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29669&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29669">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29669.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Sulfasalazine is indicated for the treatment of chronic inflammatory diseases such as rheumatoid arthritis in children and adults and ulcerative colitis. It also has off-label uses in treating patients with ankylosing spondylitis, mild to moderately active Crohn disease, psoriasis, and psoriatic arthritis.</p>
        <p>
<bold>Food and Drug Administration-Approved Indications</bold>
</p>
        <p>
<bold>Rheumatoid arthritis</bold>
</p>
        <p>The Food and Drug Administration (FDA) approved sulfasalazine for the treatment of patients with rheumatoid arthritis.&#x000a0;It is cheap, easy to administer, and lacks teratogenicity compared to other disease-modifying antirheumatic drugs.&#x000a0;There is currently no cure for rheumatoid arthritis. Non-steroidal anti-inflammatory medications and corticosteroids are frequently used to relieve pain and stiffness. However, they do not moderate disease progression. Disease-modifying antirheumatic drugs can decrease or delay disease progression. Sulfasalazine has been in use for decades as a disease-modifying antirheumatic drug.<xref ref-type="bibr" rid="article-29669.r1">[1]</xref><xref ref-type="bibr" rid="article-29669.r2">[2]</xref>&#x000a0;Newly developed biological disease-modifying antirheumatic drugs include tumor necrosis factor (TNF)-alpha inhibitors (infliximab, adalimumab, etanercept, golimumab, certolizumab), anti-CD20 antibodies (rituximab), T-cell targeted therapies (abatacept), interleukin-6 receptor antibody (tocilizumab), interleukin-1 inhibitor (anakinra), and Janus kinase inhibitor (tofacitinib).<xref ref-type="bibr" rid="article-29669.r3">[3]</xref></p>
        <p>Sulfasalazine is indicated for patients with rheumatoid arthritis who have not responded adequately to salicylates or other non-steroidal anti-inflammatory drugs. Clinical trials have proven that sulfasalazine significantly reduced disease activities, alone or in combination. According to the American College of Rheumatology 2015, sulfasalazine is part of the non-biologic disease-modifying antirheumatic drugs for managing rheumatoid arthritis patients with low to moderate or even high disease activity.<xref ref-type="bibr" rid="article-29669.r4">[4]</xref>&#x000a0;A few studies have suggested that genetic polymorphisms, especially genes involved in the folate pathway, affect the efficacy of sulfasalazine in rheumatoid arthritis; this is still an ongoing area of research. Hence, routine genetic testing is not recommended before treatment initiation.<xref ref-type="bibr" rid="article-29669.r5">[5]</xref></p>
        <p>
<bold>Polyarticular Juvenile Idiopathic Arthritis&#x000a0;</bold>
</p>
        <p>Although sulfasalazine has been used for more than&#x000a0;4 decades to treat patients with rheumatoid arthritis, the first multicenter, double-blind, and randomized controlled trial of patients with active&#x000a0;juvenile idiopathic arthritis was conducted in 1998. This study has shown that sulfasalazine is effective in treating this condition. Although treatment withdrawal due to adverse events was more frequent in the sulfasalazine-treated group, sulfasalazine was still rated as safe as those events were transient or reversible upon treatment cessation.<xref ref-type="bibr" rid="article-29669.r6">[6]</xref>&#x000a0;A follow-up study 10 years later did show significantly better outcome scores, including several active joints, patients' well-being, and duration of the clinical remission of medication in the sulfasalazine group.<xref ref-type="bibr" rid="article-29669.r7">[7]</xref></p>
        <p>
<bold>Ulcerative colitis</bold>
</p>
        <p>Sulfasalazine was initially used for patients with rheumatoid arthritis, but further study discovered that it has some role in treating patients with inflammatory bowel disease. Sulfasalazine is FDA-approved for ulcerative colitis but not FDA-approved for Crohn disease. Two randomized&#x000a0;controlled trials&#x000a0;have shown that&#x000a0;sulfasalazine was more effective than a placebo for the induction and maintenance of remission in ulcerative colitis. The current ulcerative colitis guideline suggests using&#x000a0;sulfasalazine in patients in remission who are already on&#x000a0;sulfasalazine or patients with dominant arthritic symptoms.<xref ref-type="bibr" rid="article-29669.r8">[8]</xref></p>
        <p>
<bold>Off-Label Indications</bold>
</p>
        <p>
<bold>Ankylosing spondylitis</bold>
</p>
        <p>Tumor necrosis factor (TNF) inhibitors are the favored therapeutic agents for treating ankylosing spondylitis. Sulfasalazine is used off-label for a patient who has persistent peripheral arthritis, but tumor necrosis factor inhibitors are contraindicated.<xref ref-type="bibr" rid="article-29669.r9">[9]</xref> Its usage in ankylosing spondylitis is limited to certain situations, such as no other treatment options left due to toxicity, contraindication, cost, and patient with peripheral arthritis involvement.<xref ref-type="bibr" rid="article-29669.r10">[10]</xref><xref ref-type="bibr" rid="article-29669.r11">[11]</xref>&#x000a0;In adults experiencing active ankylosing spondylitis despite undergoing treatment with non-steroidal NSAIDs, the guidelines from the American College of Rheumatology recommend considering sulfasalazine, methotrexate, or tofacitinib. Sulfasalazine is suggested specifically for patients exhibiting prominent peripheral arthritis and when TNF-&#x003b1; treatment is either unavailable or not feasible.<xref ref-type="bibr" rid="article-29669.r12">[12]</xref></p>
        <p>
<bold>Crohn disease</bold>
</p>
        <p>Sulfasalazine may serve as an alternative option for patients with mild Crohn disease based on a meta-analysis of 19&#x000a0;randomized&#x000a0;controlled trials where&#x000a0;sulfasalazine was superior to placebo in inducing remission.<xref ref-type="bibr" rid="article-29669.r13">[13]</xref><xref ref-type="bibr" rid="article-29669.r14">[14]</xref>&#x000a0;However, the evidence for its effectiveness in mucosal healing is not available and, therefore, is not strongly recommended for Crohn disease.<xref ref-type="bibr" rid="article-29669.r15">[15]</xref>&#x000a0;In contrast, sulfasalazine is the first-line therapy for mild to moderate ulcerative colitis because the disease is limited to the mucosal surface layer.&#x000a0;</p>
        <p>
<bold>Psoriatic arthritis</bold>
</p>
        <p>Psoriasis is a chronic inflammatory disease with signs and symptoms in the skin and joints. Although the first line of treatment for mild disease is a topical agent, systemic therapy is indicated for some patients with more severe disease. Monoclonal antibody biologics such as TNF-&#x003b1; blockers are useful agents for treatment. However, they should be administered by injection and have serious&#x000a0;adverse effects. Newly developed drugs such as tofacitinib (Janus kinase inhibitor) and apremilast (inhibitor of phosphodiesterase-4) are small molecules that can be given orally. Also, disease-modifying antirheumatic drugs such as methotrexate and sulfasalazine may be administered orally. The role of&#x000a0;sulfasalazine in psoriatic arthritis is limited based on current evidence that it only benefits joint and skin disease. It is less effective and tolerated than other commonly used agents such as methotrexate and leflunomide.<xref ref-type="bibr" rid="article-29669.r16">[16]</xref><xref ref-type="bibr" rid="article-29669.r17">[17]</xref><xref ref-type="bibr" rid="article-29669.r18">[18]</xref><xref ref-type="bibr" rid="article-29669.r19">[19]</xref></p>
      </sec>
      <sec id="article-29669.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The exact mechanism of&#x000a0;sulfasalazine is not fully understood. Furthermore, it is unknown whether sulfasalazine or its metabolites, such as sulfapyridine and 5-aminosalicylic acid, are responsible for its anti-inflammatory effects. The mode of action of sulfasalazine is still being investigated, including the immunological and pathological mechanisms involved in rheumatoid arthritis and inflammatory bowel disease. Sulfasalazine is a prodrug comprising 5-aminosalicylic acid (mesalamine or mesalazine) and sulfapyridine linked by an azo bond. Sulfasalazine is too big to be absorbed in the small intestine. Bacteria in the colon cleave the azo bond and liberate the active compound 5-aminosalicylic acid, which is believed to work locally in ulcerative colitis rather than systemically after being absorbed into the circulation.<xref ref-type="bibr" rid="article-29669.r20">[20]</xref></p>
        <p>The following immunomodulatory effects of sulfasalazine and its metabolites have been suggested as the underlying mechanisms of their action.</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x000a0;Sulfasalazine inhibits transcription factor nuclear factor kappa-B (NF-kB), thereby suppressing the transcription of NF-kB responsive pro-inflammatory genes, including TNF-&#x003b1;.<xref ref-type="bibr" rid="article-29669.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>&#x000a0;Sulfasalazine inhibits TNF-&#x003b1; expression by inducing caspase 8-induced apoptosis in macrophages.<xref ref-type="bibr" rid="article-29669.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>&#x000a0;Sulfasalazine inhibits osteoclast formation by suppressing receptor activators of NF-kB ligand (RANKL) expression and stimulating osteoprotegerin, a natural RANKL inhibitor.<xref ref-type="bibr" rid="article-29669.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>&#x000a0;Sulfasalazine induces the conversion of adenine nucleotides to adenosine by ecto-5&#x02019;-nucleotidase and its anti-inflammatory activities mediated by adenosine.<xref ref-type="bibr" rid="article-29669.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>&#x000a0;Salicylates and sulfasalazine inhibit leukocyte accumulation by an adenosine-dependent mechanism independent of inhibiting the NF-kB pathway or prostaglandin synthesis.<xref ref-type="bibr" rid="article-29669.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>&#x000a0;Sulfasalazine and its metabolites sulfapyridine and 5-aminosalicylic acid inhibit B cell function but not T cell function and suppress the production of IgM and IgG.<xref ref-type="bibr" rid="article-29669.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>&#x000a0;Sulfapyridine inhibits the secretion of inflammatory chemokines interleukin-8, growth-related gene product-&#x003b1;, and monocyte chemotactic protein-1.<xref ref-type="bibr" rid="article-29669.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>&#x000a0;The pro-inflammatory NF-kB signaling pathway inhibits the phosphorylation and activation of adenosine monophosphate-activated protein kinase by 5-aminosalicylic acid.<xref ref-type="bibr" rid="article-29669.r28">[28]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Following oral administration, less than 15% of a dose of sulfasalazine is absorbed as the parent drug.&#x000a0;Serum concentrations of sulfasalazine can be detected within 90 minutes of ingestion. The highest levels of sulfasalazine in the body are typically attained between 3 and 12 hours after ingestion, with the average highest concentrations occurring at around 6 hours. In comparison, peak plasma levels of sulfapyridine and 5-ASA occur for approximately 10 hours. The longer time it takes to reach peak plasma concentration suggests that the drug undergoes metabolism in the intestine by bacteria.<xref ref-type="bibr" rid="article-29669.r29">[29]</xref> Sulfapyridine is well absorbed from the colon, with an estimated bioavailability of 60%. 5-aminosalicylic acid has an estimated bioavailability of from 10% to 30%.&#x000a0;</p>
        <p><bold>Distribution:</bold> The volume of distribution for sulfasalazine is 7.5 &#x000b1; 1.6 L. Sulfasalazine is&#x000a0;primarily bound to albumin (&#x0003e;99%), while sulfapyridine is only about 70% bound to albumin. Acetylsulfapyridine, the principal metabolite of sulfapyridine, is approximately 90% bound to plasma proteins.</p>
        <p><bold>Metabolism:</bold> Sulfasalazine is metabolized by intestinal bacteria to sulfapyridine and 5 ASA. Approximately 15% of a dose of sulfasalazine is absorbed as a parent and is metabolized in the liver. 5-aminosalicylic acid is primarily metabolized in the liver and intestine to N-acetyl-5-aminosalicylic acid via a non-acetylation phenotype-dependent route.<xref ref-type="bibr" rid="article-29669.r30">[30]</xref></p>
        <p><bold>Elimination:</bold> Sulfapyridine and 5-ASA metabolites are primarily eliminated as free metabolites or glucuronide conjugates in the urine. 5-aminosalicylic acid remains within the colonic lumen and is excreted as 5-ASA and acetyl-5-ASA in the feces. The clearance of sulfasalazine is 1 L/hr. Renal clearance is estimated to account for 37% of total body clearance.&#x000a0;The plasma half-life for sulfasalazine is 7.6 &#x000b1; 3.4 hrs. The rate of metabolism of sulfapyridine to acetyl-sulfapyridine is dependent upon acetylator phenotype. In fast acetylators, the mean half-life of sulfapyridine is 10.4 hrs, while in slow acetylators it is 14.8 hrs.</p>
      </sec>
      <sec id="article-29669.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Sulfasalazine is available in 500 mg oral tablets in immediate and delayed-release formulations. Delayed-release tablets should not be chewed and swallowed whole. Administration is preferable after meals.&#x000a0;</p>
        <p><bold>Adult dosage:&#x000a0;</bold>Clinical indication directs dosing guidelines in adults.</p>
        <list list-type="bullet">
          <list-item>
            <p>Rheumatoid arthritis: 500 mg once daily or 1 g per day in 2 divided doses up to a maximum of 3 g per day in divided doses.</p>
          </list-item>
          <list-item>
            <p>Ulcerative colitis: The initial dose is 3 to 4 g per day divided into doses at less than equal 8-hour intervals. The maintenance dose is 2 g per day divided into doses at less than equal 8-hour intervals.</p>
          </list-item>
          <list-item>
            <p>Crohn disease: 3 to 6 g per day in divided doses up to 16 weeks.</p>
          </list-item>
          <list-item>
            <p>Psoriatic arthritis: initial 500 mg once daily up to 2 to 3 g daily.</p>
          </list-item>
          <list-item>
            <p>Ankylosing spondylitis (off-label): 500 mg or daily up to 2 to 3 g per day in divided doses.<xref ref-type="bibr" rid="article-29669.r31">[31]</xref></p>
          </list-item>
        </list>
        <p>There is a desensitization regimen for patients who may be hypersensitive to treatment. The recommendation is to start with a daily dose of 50 to 250 mg and double it every 4 to 7 days until achieving the therapeutic level.&#x000a0;Discontinue the drug if symptoms of hypersensitivity occur.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> The product labeling does not include dosage adjustments for sulfasalazine;&#x000a0;use with caution.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;Sulfasalazine is associated with nephrolithiasis, especially in patients with inflammatory bowel disease undergoing sulfasalazine therapy. Ensuring hydration is essential to mitigate this complication.<xref ref-type="bibr" rid="article-29669.r32">[32]</xref>&#x000a0;Acute interstitial nephritis is a severe adverse event, and early recognition, along with the prompt discontinuation of sulfasalazine, is required.<xref ref-type="bibr" rid="article-29669.r33">[33]</xref></p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Sulfasalazine and its metabolite sulfapyridine can cross the placental barrier. Instances of neural tube defects (NTDs) in infants born to mothers exposed to sulfasalazine during pregnancy have been documented. According to the American Gastroenterological Association, sulfasalazine can be considered during pregnancy with&#x000a0;folate supplementation.<xref ref-type="bibr" rid="article-29669.r34">[34]</xref></p>
        <p><bold>Breastfeeding considerations:</bold> Sulfasalazine and its active metabolite mesalamine exhibit limited excretion into breast milk. Sulfasalazine metabolite, sulfapyridine, is detected in both milk and infant serum, posing a potential risk of hemolysis, particularly in newborns and those with glucose-6-phosphate dehydrogenase (G6PD) deficiency. The highest risk of hemolysis in full-term newborns without G6PD deficiency is&#x000a0;8 days post-birth. Most experts generally regard mesalamine derivatives as safe for breastfeeding. In situations where maternal sulfasalazine use is necessary, discontinuing breastfeeding is not typically warranted. However, close monitoring of breastfed infants for diarrhea is advised. Preferential consideration is given to mesalamine derivatives that lack a sulfonamide component.<xref ref-type="bibr" rid="article-29669.r35">[35]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;The safety and efficacy of sulfasalazine in patients&#x000a0;younger than&#x000a0;2 years old have not been documented.&#x000a0;For juvenile idiopathic arthritis patients aged 6 to 16, the recommended dosage is 30 to 50 mg/kg/d, administered in&#x000a0;2 divided doses, with a maximum daily limit of 2 g.</p>
        <p><bold>Older adults:</bold> Older adults with rheumatoid arthritis demonstrated an extended plasma half-life for sulfasalazine, sulfapyridine, and their respective metabolites.</p>
      </sec>
      <sec id="article-29669.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The&#x000a0;most common&#x000a0;adverse effects include nausea, vomiting, anorexia, dyspepsia, male infertility (reversible), headache, and skin rash. The skin rashes related to its use include urticaria, maculopapular lesions, and blue discoloration.<xref ref-type="bibr" rid="article-29669.r36">[36]</xref> The most severe skin hypersensitivity reaction is toxic epidermal necrosis.<xref ref-type="bibr" rid="article-29669.r37">[37]</xref>&#x000a0;In a study of more than 250 men exposed to sulfasalazine, researchers found the subjects to have oligospermia, abnormal sperm motility, and morphology, all of which were reversible within&#x000a0;3 months of stopping&#x000a0;sulfasalazine treatment.<xref ref-type="bibr" rid="article-29669.r38">[38]</xref>&#x000a0;The less common reactions include leukopenia, thrombocytopenia, hemolytic anemia, abnormal liver function tests, fever, and dizziness. Reports exist of the most serious&#x000a0;adverse effects affecting almost every organ, but they are rare. A few case reports showed some relationships between sulfasalazine use and Epstein-Barr virus-associated hypersensitivity syndrome, granulomatosis with polyangiitis, and hemophagocytic syndrome.<xref ref-type="bibr" rid="article-29669.r39">[39]</xref><xref ref-type="bibr" rid="article-29669.r40">[40]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The inhibition of thiopurine methyl transferase enzyme activity by sulfasalazine&#x000a0;can potentially enhance the toxicity of azathioprine.<xref ref-type="bibr" rid="article-29669.r41">[41]</xref></p>
          </list-item>
          <list-item>
            <p>Sulfasalazine exerts&#x000a0;inhibits&#x000a0;the gastrointestinal absorption of digoxin, resulting in diminished bioavailability. Use with caution.</p>
          </list-item>
          <list-item>
            <p>Sulfasalazine infrequently may potentiate the effects of oral hypoglycemic medications and augment the anticoagulant impact of warfarin.<xref ref-type="bibr" rid="article-29669.r30">[30]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29669.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to sulfasalazine include patients with hypersensitivity to sulfasalazine, its metabolite, sulfonamides, salicylates, or any component of the formulation, intestinal or urinary obstruction, and porphyria.<xref ref-type="bibr" rid="article-29669.r30">[30]</xref></p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p><bold>Acetylator status:</bold> The metabolism of sulfapyridine (SP) into acetylated sulfapyridine (AcSP) is influenced by polymorphic enzymes, leading to&#x000a0;2 distinct groups of individuals categorized as slow and fast acetylators. Roughly 60% of the Caucasian population falls into the category of slow acetylators. These individuals exhibit an extended plasma half-life for sulfapyridine (14.8 hours compared to 10.4 hours) and accumulate higher sulfapyridine levels in their plasma compared to fast acetylators. There is a potential association between being a slow acetylator of sulfapyridine and a higher likelihood of experiencing adverse events.<xref ref-type="bibr" rid="article-29669.r42">[42]</xref></p>
        <p><bold>Allergic reactions:</bold> The administration of sulfasalazine tablets warrants caution in individuals with pronounced allergic reactions. Sulfasalazine-induced hypersensitivity syndrome has been reported.<xref ref-type="bibr" rid="article-29669.r43">[43]</xref></p>
        <p><bold>Crystalluria:</bold> Ensuring sufficient fluid intake is imperative to mitigate the risk of crystalluria and the formation of stones.<xref ref-type="bibr" rid="article-29669.r44">[44]</xref></p>
        <p><bold>G6PD deficiency:</bold> Close monitoring for signs of hemolytic anemia is essential in patients with glucose-6-phosphate dehydrogenase deficiency.<xref ref-type="bibr" rid="article-29669.r45">[45]</xref></p>
      </sec>
      <sec id="article-29669.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>There are reports of blood dyscrasias, pancreatitis, interstitial nephritis, hepatitis, and hepatic failure in patients treated with 5-aminosalicylic acid or sulfasalazine.<xref ref-type="bibr" rid="article-29669.r46">[46]</xref>&#x000a0;The&#x000a0;baseline level of complete blood count, serum creatinine, and liver function test should be obtained before initiating pharmacotherapy with sulfasalazine.&#x000a0;The test&#x000a0;should be repeated every 2 to 4 weeks for the first&#x000a0;3 months after&#x000a0;the start of treatment or following an increase in dose, then every 8 to 12 weeks during the subsequent&#x000a0;3 months and every 12 weeks afterward. Serious cutaneous&#x000a0;adverse&#x000a0;reactions such as&#x000a0;toxic epidermal necrolysis require&#x000a0;prompt discontinuation&#x000a0;and intensive treatment.<xref ref-type="bibr" rid="article-29669.r47">[47]</xref><xref ref-type="bibr" rid="article-29669.r48">[48]</xref></p>
      </sec>
      <sec id="article-29669.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Dose-related toxicity of&#x000a0;sulfasalazine includes gastrointestinal upset such as nausea, vomiting, diarrhea, and anorexia, central nervous system symptoms like headache, and hematologic manifestations including leukopenia, hemolytic anemia, macrocytosis, and megaloblastic anemia.&#x000a0;Patients require monitoring for signs of respiratory distress and other vital signs.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>There is no specific antidote for&#x000a0;sulfasalazine overdose toxicity. The healthcare team should provide supportive and symptomatic care.&#x000a0;Patients receiving&#x000a0;sulfasalazine&#x000a0;are at an increased risk of urolithiasis and may benefit from adequate hydration and urinary alkalization.<xref ref-type="bibr" rid="article-29669.r49">[49]</xref><xref ref-type="bibr" rid="article-29669.r44">[44]</xref></p>
      </sec>
      <sec id="article-29669.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Sulfasalazine has been widely used to treat inflammatory bowel disease and rheumatoid arthritis.<xref ref-type="bibr" rid="article-29669.r36">[36]</xref>&#x000a0;Rheumatology and gastroenterology are the&#x000a0;2 fields that utilize this drug extensively in managing these diseases. Seeing patients in daily practice with these diseases maintained with sulfasalazine is not unusual; collaborating with the primary care team and other specialists is essential for effective management. As mentioned above, the physician must recognize the adverse reactions and contraindications.</p>
        <p>Patients with decreased blood cell count while using this drug should prompt the health care provider to adjust or even stop this drug with notification to the prescriber (usually a specialist). Physicians, nurses, and pharmacists must verify the allergic history before prescribing and dispensing sulfasalazine. The pharmacists should also assist the team by verifying appropriate dosing and monitoring interactions with other drugs. Sulfasalazine therapy requires the involvement and coordination of an interprofessional team, including clinicians, specialists, nurses, and pharmacists, to ensure optimal patient outcomes.</p>
      </sec>
      <sec id="article-29669.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29669&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29669">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29669/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29669">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29669.s11">
        <title>References</title>
        <ref id="article-29669.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plosker</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Croom</surname>
                <given-names>KF</given-names>
              </name>
            </person-group>
            <article-title>Sulfasalazine: a review of its use in the management of rheumatoid arthritis.</article-title>
            <source>Drugs</source>
            <year>2005</year>
            <volume>65</volume>
            <issue>13</issue>
            <fpage>1825</fpage>
            <page-range>1825-49</page-range>
            <pub-id pub-id-type="pmid">16114981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rains</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Noble</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Faulds</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis.</article-title>
            <source>Drugs</source>
            <year>1995</year>
            <month>Jul</month>
            <volume>50</volume>
            <issue>1</issue>
            <fpage>137</fpage>
            <page-range>137-56</page-range>
            <pub-id pub-id-type="pmid">7588084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guo</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nossent</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pavlos</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies.</article-title>
            <source>Bone Res</source>
            <year>2018</year>
            <volume>6</volume>
            <fpage>15</fpage>
            <pub-id pub-id-type="pmid">29736302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Saag</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Bridges</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Akl</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Bannuru</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Vaysbrot</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McNaughton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Osani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shmerling</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Furst</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Parks</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kavanaugh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Dell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Schousboe</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Drevlow</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ginsberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grober</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>St Clair</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Tindall</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>McAlindon</surname>
                <given-names>T</given-names>
              </name>
              <collab>American College of Rheumatology</collab>
            </person-group>
            <article-title>2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>68</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-25</page-range>
            <pub-id pub-id-type="pmid">26545825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>James</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Gillis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hissaria</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lester</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Somogyi</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Cleland</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Proudman</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.</article-title>
            <source>J Rheumatol</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>562</fpage>
            <page-range>562-71</page-range>
            <pub-id pub-id-type="pmid">18322994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Rossum</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Fiselier</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Franssen</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Zwinderman</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>ten Cate</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van Suijlekom-Smit</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>van Luijk</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>van Soesbergen</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Wulffraat</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Oostveen</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kuis</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Dijkstra</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>van Ede</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Dijkmans</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group.</article-title>
            <source>Arthritis Rheum</source>
            <year>1998</year>
            <month>May</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>808</fpage>
            <page-range>808-16</page-range>
            <pub-id pub-id-type="pmid">9588731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Rossum</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>van Soesbergen</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Boers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zwinderman</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Fiselier</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Franssen</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>ten Cate</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van Suijlekom-Smit</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Wulffraat</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>van Luijk</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Oostveen</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kuis</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Dijkmans</surname>
                <given-names>BA</given-names>
              </name>
              <collab>Dutch Juvenile Idiopathic Arthritis Study group</collab>
            </person-group>
            <article-title>Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>66</volume>
            <issue>11</issue>
            <fpage>1518</fpage>
            <page-range>1518-24</page-range>
            <pub-id pub-id-type="pmid">17491099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ko</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Feuerstein</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Falck-Ytter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Falck-Ytter</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cross</surname>
                <given-names>RK</given-names>
              </name>
              <collab>American Gastroenterological Association Institute Clinical Guidelines Committee</collab>
            </person-group>
            <article-title>AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis.</article-title>
            <source>Gastroenterology</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>156</volume>
            <issue>3</issue>
            <fpage>748</fpage>
            <page-range>748-764</page-range>
            <pub-id pub-id-type="pmid">30576644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ward</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deodhar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gensler</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Dubreuil</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Haroon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Borenstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Biehl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Louie</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Majithia</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bigham</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pianin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Turgunbaev</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oristaglio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maksymowych</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Caplan</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>71</volume>
            <issue>10</issue>
            <fpage>1599</fpage>
            <page-range>1599-1613</page-range>
            <pub-id pub-id-type="pmid">31436036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Braun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van den Berg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Baraliakos</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Boehm</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Burgos-Vargas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Collantes-Estevez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dagfinrud</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dijkmans</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dougados</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Emery</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Geher</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hammoudeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Inman</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Jongkees</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kiltz</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kvien</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Leirisalo-Repo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maksymowych</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Olivieri</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pavelka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sieper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stanislawska-Biernat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wendling</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ozgocmen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van Drogen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>van Royen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>van der Heijde</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>70</volume>
            <issue>6</issue>
            <fpage>896</fpage>
            <page-range>896-904</page-range>
            <pub-id pub-id-type="pmid">21540199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Sulfasalazine for ankylosing spondylitis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>Nov</month>
            <day>27</day>
            <volume>2014</volume>
            <issue>11</issue>
            <fpage>CD004800</fpage>
            <pub-id pub-id-type="pmid">25427435</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ward</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deodhar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gensler</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Dubreuil</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Haroon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Borenstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Biehl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Louie</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Majithia</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bigham</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pianin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Turgunbaev</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oristaglio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maksymowych</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Caplan</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>71</volume>
            <issue>10</issue>
            <fpage>1285</fpage>
            <page-range>1285-1299</page-range>
            <pub-id pub-id-type="pmid">31436026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Hanauer</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Aminosalicylates for induction of remission or response in Crohn's disease.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2016</year>
            <month>Jul</month>
            <day>03</day>
            <volume>7</volume>
            <issue>7</issue>
            <fpage>CD008870</fpage>
            <pub-id pub-id-type="pmid">27372735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Croke</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Crohn's Disease: ACG Releases Updated Management Guidelines.</article-title>
            <source>Am Fam Physician</source>
            <year>2018</year>
            <month>Dec</month>
            <day>15</day>
            <volume>98</volume>
            <issue>12</issue>
            <fpage>756</fpage>
            <page-range>756-757</page-range>
            <pub-id pub-id-type="pmid">30525353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lichtenstein</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>Highlights From the New ACG Guideline on Crohn's Disease Management.</article-title>
            <source>Gastroenterol Hepatol (N Y)</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>8</issue>
            <fpage>482</fpage>
            <page-range>482-484</page-range>
            <pub-id pub-id-type="pmid">30302063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dougados</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>vam der Linden</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leirisalo-Repo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huitfeldt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Juhlin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Veys</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zeidler</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kvien</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Olivieri</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dijkmans</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study.</article-title>
            <source>Arthritis Rheum</source>
            <year>1995</year>
            <month>May</month>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>618</fpage>
            <page-range>618-27</page-range>
            <pub-id pub-id-type="pmid">7748217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Grober</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Voorhees</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>McCune</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial.</article-title>
            <source>J Rheumatol</source>
            <year>1995</year>
            <month>May</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>894</fpage>
            <page-range>894-8</page-range>
            <pub-id pub-id-type="pmid">8587078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Korman</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Elmets</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Gelfand</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Koo</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Lebwohl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Van Voorhees</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Beutner</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Bhushan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>61</volume>
            <issue>3</issue>
            <fpage>451</fpage>
            <page-range>451-85</page-range>
            <pub-id pub-id-type="pmid">19493586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelly</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Foley</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Strober</surname>
                <given-names>BE</given-names>
              </name>
            </person-group>
            <article-title>Current and future oral systemic therapies for psoriasis.</article-title>
            <source>Dermatol Clin</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>91</fpage>
            <page-range>91-109</page-range>
            <pub-id pub-id-type="pmid">25412786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peppercorn</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The role of intestinal bacteria in the metabolism of salicylazosulfapyridine.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>1972</year>
            <month>Jun</month>
            <volume>181</volume>
            <issue>3</issue>
            <fpage>555</fpage>
            <page-range>555-62</page-range>
            <pub-id pub-id-type="pmid">4402374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wahl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liptay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Adler</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B.</article-title>
            <source>J Clin Invest</source>
            <year>1998</year>
            <month>Mar</month>
            <day>01</day>
            <volume>101</volume>
            <issue>5</issue>
            <fpage>1163</fpage>
            <page-range>1163-74</page-range>
            <pub-id pub-id-type="pmid">9486988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodenburg</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Ganga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Lent</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>van de Putte</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>van Venrooij</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis.</article-title>
            <source>Arthritis Rheum</source>
            <year>2000</year>
            <month>Sep</month>
            <volume>43</volume>
            <issue>9</issue>
            <fpage>1941</fpage>
            <page-range>1941-50</page-range>
            <pub-id pub-id-type="pmid">11014343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Mun</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>HB</given-names>
              </name>
            </person-group>
            <article-title>Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.</article-title>
            <source>Arthritis Rheum</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>50</volume>
            <issue>12</issue>
            <fpage>3831</fpage>
            <page-range>3831-43</page-range>
            <pub-id pub-id-type="pmid">15593184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morabito</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Montesinos</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Schreibman</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Balter</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Resta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Carlin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Huie</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Cronstein</surname>
                <given-names>BN</given-names>
              </name>
            </person-group>
            <article-title>Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides.</article-title>
            <source>J Clin Invest</source>
            <year>1998</year>
            <month>Jan</month>
            <day>15</day>
            <volume>101</volume>
            <issue>2</issue>
            <fpage>295</fpage>
            <page-range>295-300</page-range>
            <pub-id pub-id-type="pmid">9435300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cronstein</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Montesinos</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Weissmann</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>1999</year>
            <month>May</month>
            <day>25</day>
            <volume>96</volume>
            <issue>11</issue>
            <fpage>6377</fpage>
            <page-range>6377-81</page-range>
            <pub-id pub-id-type="pmid">10339595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirohata</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ohshima</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yanagida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aramaki</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Regulation of human B cell function by sulfasalazine and its metabolites.</article-title>
            <source>Int Immunopharmacol</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>2</volume>
            <issue>5</issue>
            <fpage>631</fpage>
            <page-range>631-40</page-range>
            <pub-id pub-id-type="pmid">12013503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Volin</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Woodruff</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>The effect of sulfasalazine on rheumatoid arthritic synovial tissue chemokine production.</article-title>
            <source>Exp Mol Pathol</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>73</volume>
            <issue>2</issue>
            <fpage>84</fpage>
            <page-range>84-92</page-range>
            <pub-id pub-id-type="pmid">12231210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Mesalazine Activates Adenosine Monophosphate-activated Protein Kinase: Implication in the Anti-inflammatory Activity of this Anti-colitic Drug.</article-title>
            <source>Curr Mol Pharmacol</source>
            <year>2019</year>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>272</fpage>
            <page-range>272-280</page-range>
            <pub-id pub-id-type="pmid">30848228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crouwel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Buiter</surname>
                <given-names>HJC</given-names>
              </name>
              <name>
                <surname>de Boer</surname>
                <given-names>NK</given-names>
              </name>
            </person-group>
            <article-title>Gut microbiota-driven drug metabolism in inflammatory bowel disease.</article-title>
            <source>J Crohns Colitis</source>
            <year>2020</year>
            <month>Jul</month>
            <day>11</day>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>307</fpage>
            <page-range>307-15</page-range>
            <pub-id pub-id-type="pmid">32652007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mushtaq</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sarkar</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Sulfasalazine in dermatology: A lesser explored drug with broad therapeutic potential.</article-title>
            <source>Int J Womens Dermatol</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>191</fpage>
            <page-range>191-198</page-range>
            <pub-id pub-id-type="pmid">32637543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Braun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van der Horst-Bruinsma</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Burgos-Vargas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vlahos</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Koenig</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Freundlich</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial.</article-title>
            <source>Arthritis Rheum</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>63</volume>
            <issue>6</issue>
            <fpage>1543</fpage>
            <page-range>1543-51</page-range>
            <pub-id pub-id-type="pmid">21630245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Durando</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tiu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Sulfasalazine-Induced Crystalluria Causing Severe Acute&#x000a0;Kidney&#x000a0;Injury.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>70</volume>
            <issue>6</issue>
            <fpage>869</fpage>
            <page-range>869-873</page-range>
            <pub-id pub-id-type="pmid">28669550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dargavel</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>What about the role of sulfasalazine?</article-title>
            <source>CMAJ</source>
            <year>2013</year>
            <month>Jul</month>
            <day>09</day>
            <volume>185</volume>
            <issue>10</issue>
            <fpage>899</fpage>
            <pub-id pub-id-type="pmid">23836921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahadevan</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bernasko</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Boland</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chambers</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dubinsky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Manthey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sauberan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Inflammatory Bowel Disease in Pregnancy Clinical&#x000a0;Care Pathway: A Report From the American Gastroenterological Association IBD&#x000a0;Parenthood Project Working Group.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>220</volume>
            <issue>4</issue>
            <fpage>308</fpage>
            <page-range>308-323</page-range>
            <pub-id pub-id-type="pmid">30948039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r35">
          <label>35</label>
          <element-citation publication-type="book">
            <chapter-title>Sulfasalazine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peppercorn</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development.</article-title>
            <source>Ann Intern Med</source>
            <year>1984</year>
            <month>Sep</month>
            <volume>101</volume>
            <issue>3</issue>
            <fpage>377</fpage>
            <page-range>377-86</page-range>
            <pub-id pub-id-type="pmid">6147110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Str&#x000f6;m</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Toxic epidermal necrolysis (Leyell's syndrome). A report on four cases with three deaths.</article-title>
            <source>Scand J Infect Dis</source>
            <year>1969</year>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>209</fpage>
            <page-range>209-16</page-range>
            <pub-id pub-id-type="pmid">4398608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mouyis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Flint</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Giles</surname>
                <given-names>IP</given-names>
              </name>
            </person-group>
            <article-title>Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>48</volume>
            <issue>5</issue>
            <fpage>911</fpage>
            <page-range>911-920</page-range>
            <pub-id pub-id-type="pmid">30220537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Denissen</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Masereeuw</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Barrera</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Can sulfasalazine therapy induce or exacerbate Wegener's granulomatosis?</article-title>
            <source>Scand J Rheumatol</source>
            <year>2008</year>
            <season>Jan-Feb</season>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-4</page-range>
            <pub-id pub-id-type="pmid">18189198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Komatsuda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Okamoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hatakeyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wakui</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sawada</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.</article-title>
            <source>Clin Rheumatol</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>395</fpage>
            <page-range>395-7</page-range>
            <pub-id pub-id-type="pmid">17952482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anstey</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Wakelin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>NJ</given-names>
              </name>
              <collab>British Association of Dermatologists Therapy, Guidelines and Audit Subcommittee</collab>
            </person-group>
            <article-title>Guidelines for prescribing azathioprine in dermatology.</article-title>
            <source>Br J Dermatol</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>151</volume>
            <issue>6</issue>
            <fpage>1123</fpage>
            <page-range>1123-32</page-range>
            <pub-id pub-id-type="pmid">15606506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Gwak</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis.</article-title>
            <source>Sci Rep</source>
            <year>2020</year>
            <month>Feb</month>
            <day>27</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>3658</fpage>
            <pub-id pub-id-type="pmid">32107440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Winward</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lyckholm</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Mokadem</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Case of relapsing sulfasalazine-induced hypersensitivity syndrome upon re-exposure.</article-title>
            <source>BMJ Case Rep</source>
            <year>2020</year>
            <month>Sep</month>
            <day>15</day>
            <volume>13</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">32933910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bianchi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gaiani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bizzarri</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Minelli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cortegoso Valdivia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leandro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Di Mario</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>De' Angelis</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Ruberto</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Renal lithiasis and inflammatory bowel diseases, an update on pediatric population.</article-title>
            <source>Acta Biomed</source>
            <year>2018</year>
            <month>Dec</month>
            <day>17</day>
            <volume>89</volume>
            <issue>9-S</issue>
            <fpage>76</fpage>
            <page-range>76-80</page-range>
            <pub-id pub-id-type="pmid">30561398</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luzzatto</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ally</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Notaro</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Glucose-6-phosphate dehydrogenase deficiency.</article-title>
            <source>Blood</source>
            <year>2020</year>
            <month>Sep</month>
            <day>10</day>
            <volume>136</volume>
            <issue>11</issue>
            <fpage>1225</fpage>
            <page-range>1225-1240</page-range>
            <pub-id pub-id-type="pmid">32702756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ransford</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Langman</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.</article-title>
            <source>Gut</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>536</fpage>
            <page-range>536-9</page-range>
            <pub-id pub-id-type="pmid">12235076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shahidi-Dadras</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shahrigharahkoshan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yazdi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fatemi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mahboubi-Fooladi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Dadkhahfar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Sulfasalazine-Induced Toxic Epidermal Necrolysis: A Challenging Case During the COVID-19 Pandemic.</article-title>
            <source>Adv Emerg Nurs J</source>
            <string-date>2021 Jul-Sep 01</string-date>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>194</fpage>
            <page-range>194-197</page-range>
            <pub-id pub-id-type="pmid">34397495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zizi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Elmrahi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dikhaye</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fihmi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Alami</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Stevens Johnson syndrome-Toxic Epidermal Necrolysis Overlap induced by sulfasalazine treatment: a case report.</article-title>
            <source>Tunis Med</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>93</volume>
            <issue>7</issue>
            <fpage>413</fpage>
            <page-range>413-5</page-range>
            <pub-id pub-id-type="pmid">26757493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29669.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Russinko</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kelty</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Obstructive nephropathy secondary to sulfasalazine calculi.</article-title>
            <source>Urology</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>62</volume>
            <issue>4</issue>
            <fpage>748</fpage>
            <pub-id pub-id-type="pmid">14550462</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
